Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure.
On October 11, 2018, Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) issued a press release announcing the Company’s plans to advance I-131 1095, the Company’s prostate specific membrane antigen (PSMA)-targeted therapeutic, into a Phase 2 clinical study. I-131 1095 is a small molecule radiotherapeutic designed to selectively bind to the extracellular domain of PSMA, a protein that is expressed on prostate cancer cells. A copy of the foregoing press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated in this Item 7.01 by reference.
The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01Financial Statements and Exhibits
(d)Exhibits.
PROGENICS PHARMACEUTICALS INC ExhibitEX-99.1 2 ex_125377.htm EXHIBIT 99.1 ex_125377.htm Exhibit 99.1 Progenics Pharmaceuticals,…To view the full exhibit click here
About Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)
Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence-based approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces an automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ([18F] DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor-Subcutaneous injection, Relistor-Oral Tablets and PRO 140.